



Melanoma
World Society
MWS

Under the auspices
of the Melanoma
World Society

Final Program

Cape Town, South Africa
March 3rd–4th, 2017

SKIN CANCER UPDATE 2017

First International MWS Educational Symposium

Course Directors


Claus Garbe, Tuebingen, Germany

Axel Hauschild, Kiel, Germany

Daniel Vorobiof, Johannesburg, South Africa

Dagmar Whitaker, Cape Town, South Africa

www.melanomaworldsociety.org/events



CONTENT

WELCOME MESSAGE 1

MISSION 2

FINAL PROGRAM 3

COURSE FACULTY 8

SATELLITE SYMPOSIUM 11

GENERAL INFORMATION 12

SPONSORS 16

Dear Ladies and Gentlemen,

The Melanoma World Society (MWS) is the successor organization to the WHO Melanoma Group. The latter established the World Congress of Melanoma in the years 1985–2005, conducted trials and other projects with melanoma patients. The WHO melanoma group was disbanded in 2005, as WHO no longer financially supported such expert groups. MWS was initiated at the 8th World Congress of Melanoma 2013 in Hamburg, founded in June 2014 in Munich, and registered in January 2016.

The First MWS International Educational Symposium – Skin Cancer Updated 2017 is the first of a series of educational meetings organized under the auspices of the Melanoma World Society. It is intended to organize the meeting in different countries annually.

International and national key opinion leaders on skin cancer will be invited to give an overview throughout specified presentations, to present latest clinical trial results, and to discuss on exciting new drugs, technologies and methods of treatment with the audience. The lively interaction of clinicians, as well as experts in translational and basic research, and representatives of the pharmaceutical industry, guarantees a successful outcome for every participant. In addition to the scientific value of this meeting, every participant may seize the given opportunity to interact with experts in a familiar setting in one of the most interesting cities of South Africa.

Please join us for this event and submit your own studies and case presentations as free communications and as posters.

We look forward to welcoming you in Cape Town in March 2017!

With kind regards



Claus Garbe, MD



Axel Hauschild, MD



Daniel Vorobiof, MD



Dagmar Whitaker, MD

Scientific Directors

WELCOME MESSAGE

The following missions will guide the activities of MWS:

Improve Medical Education

MWS will host the World Congress of Melanoma every four years, following the tradition since 1985. MWS will care for grants in order to make attendance of physicians from developing countries possible. MWS will organize the World Meeting of Melanoma/Skin Cancer Centers annually in between the World Congress of Melanoma. MWS will support educational meetings in countries with less experience in melanoma diagnosis and treatment.

Improve Guideline Development

MWS intends to unify diagnostic and therapeutic strategies in melanoma worldwide. MWS will establish a MELANOMA KNOWLEDGE DATABASE (MKD), which contains all relevant articles for evidence based medicine in melanoma, and additionally evidence tables of these articles. MKD will be accessible for all national guideline groups. MWS will organize international expert meetings in order to develop recommendations for diagnosis and treatment of melanoma in the rapidly changing landscape.

Improve Patient's Access to New Treatments

MWS intends to provide melanoma patients worldwide access to new and more efficacious treatments. MWS will address governments in order to achieve a more rapid reimbursement of new treatments. MWS will address pharmaceutical companies in order to achieve access to new treatment modalities in countries, where the high costs cannot be reimbursed.

Improve Clinical Research in Melanoma

MWS will coordinate clinical research activities in melanoma internationally. MWS will perform international clinical trials in indications, which are not investigated by the pharmaceutical industries. MWS will support international expert meetings in order to coordinate clinical research.

Friday, March 3rd, 2017

08:00–09:00 Molecular biology of melanoma

Chairs: Dirk Schadendorf, Charles Thatcher

08:00–08:15 Biology of melanoma: From melanocytic nevus to metastatic melanoma
Dirk Schadendorf, Essen, Germany

08:20–08:35 Molecular testing in melanoma
Christopher Philipp Maske, Johannesburg, South Africa

08:40–08:55 Panel discussion
Helen Gogas, Athens, Greece
Christopher Philipp Maske, Johannesburg, South Africa
Dirk Schadendorf, Essen, Germany
Charles Thatcher, Johannesburg, South Africa

09:00–10:00 Epidemiology of skin cancer

Chairs: Claus Garbe, Dagmar Whitaker

09:00–09:15 Global incidence of skin cancer
Claus Garbe, Tuebingen, Germany

09:20–09:35 Global mortality of melanoma
Jean Jacques Grob, Marseille, France

09:40–09:55 Melanoma in South Africa
Dagmar Whitaker, Cape Town, South Africa

10:00–10:30 Coffee Break

10:30–11:30 Early detection of melanoma

Chairs: Axel Hauschild, Gary Levy

10:30–10:45 New devices for skin cancer diagnosis
Axel Hauschild, Kiel, Germany

10:50–11:05 Early detection by dermoscopy
Gary Levy, Johannesburg, South Africa

11:10–11:25 Population based skin cancer screening in Germany
Axel Hauschild, Kiel, Germany

FINAL PROGRAM

11:30–12:30 Surgery**Chairs: Roland Kaufmann, Peter Scott**

11:30–11:45 Surgery of non-melanoma skin cancers
Peter Scott, Johannesburg, South Africa

11:50–12:05 Surgery of melanoma primaries and regional nodes
Roland Kaufmann, Frankfurt, Germany

12:10–12:25 Panel discussion
Axel Hauschild, Kiel, Germany
Roland Kaufmann, Frankfurt, Germany
Alex Landau, Cape Town, South Africa
Peter Scott, Johannesburg, South Africa

12:30–12:45 Break

12:45–13:45 Satellite Symposium with lunch bags
(gold sponsor) *(see page 11)*

13:45–14:00 Break

14:00–15:00 Adjuvant treatment**Chairs: Helen Gogas, Daniel Vorobiof**

14:00–14:15 Adjuvant interferon treatment
Daniel Vorobiof, Johannesburg, South Africa

14:20–14:35 Future developments of adjuvant treatment of melanoma
Axel Hauschild, Kiel, Germany

14:40–14:55 Panel discussion
Helen Gogas, Athens, Greece
Axel Hauschild, Kiel, Germany
Daniel Vorobiof, Johannesburg, South Africa

15:00–16:00 Targeted therapy of melanoma**Chairs: Dirk Schadendorf, Daniel Vorobiof**

15:00–15:15 Update on targeted therapies in melanoma
Dirk Schadendorf, Essen, Germany

15:20–15:35 Management of adverse events
Lucie Heinzerling, Erlangen, Germany

15:40–16:00 Panel discussion: Patient access to new medication initiative of the MWS/global and RSA
Dirk Schadendorf, Essen, Germany
Daniel Vorobiof, Johannesburg, South Africa
Dagmar Whitaker, Cape Town, South Africa

16:00–16:30 Coffee Break

16:30–17:30 Immunotherapy of melanoma

Chairs: Dirk Schadendorf, Bernardo Leon Rapoport

16:30–16:45 Overview on immune checkpoint modulators
Devan Moodley, Durban, South Africa

16:50–17:05 Future perspectives of immunotherapy
Dirk Schadendorf, Essen, Germany

17:10–17:25 Management of adverse events
Lucie Heinzerling, Erlangen, Germany

17:30–18:30 Systemic treatment of non-melanoma skin cancers

Chairs: Jean Jacques Grob, Suretha Kannenberg

17:30–17:45 Basal cell carcinoma
Suretha Kannenberg, Cape Town, South Africa

17:50–18:05 Merkel cell carcinoma
Rainer Kunstfeld, Vienna, Austria

18:10–18:25 Squamous cell carcinoma
Jean Jacques Grob, Marseille, France

18:30 End of sessions

18:30–19:30 Networking Evening at The Rotunda

Saturday, March 4th, 2017

08:00–09:00 Prevention of skin cancer

Chairs: Adele Green, Dagmar Whitaker

08:00–08:15 The role of sunscreens
Adele Green, Brisbane, Australia

08:20–08:35 Prevention in Australia
Adele Green, Brisbane, Australia

08:40–08:55 Prevention in South Africa
Dagmar Whitaker, Cape Town, South Africa

09:00–10:00 Rare skin tumors

Chairs: Roland Kaufmann, Willie Visser

09:00–09:15 Differential diagnosis of rare skin cancers
Willie Visser, Cape Town, South Africa

09:20–09:35 Adnexal tumors
Charles Thatcher, Johannesburg, South Africa

09:40–09:55 Surgery in rare skin cancers
Roland Kaufmann, Frankfurt, Germany

10:00–10:30 Coffee Break with guided Poster Viewing

10:30–11:30 Guidelines development and interdisciplinary skin cancer centers

Chairs: Claus Garbe, Devan Moodley

10:30–10:45 Guideline development for melanoma and NMSC
Claus Garbe, Tuebingen, Germany

10:50–11:05 Interdisciplinary cooperation in dermatooncology in South Africa
Devan Moodley, Durban, South Africa

11:10–11:25 European development of interdisciplinary skin cancer centers
Claus Garbe, Tuebingen, Germany

11:30–12:30 Follow-up examinations in melanoma

Chairs: Claus Garbe, Dagmar Whitaker

11:30–11:40 Follow-up of melanoma in Germany
Claus Garbe, Tuebingen, Germany

11:40–11:50 Follow-up of melanoma in South Africa
Dagmar Whitaker, Cape Town, South Africa

11:50–12:30 Panel discussion: Optimizing melanoma
follow-up
Claus Garbe, Tuebingen, Germany
Daniel Vorobiof, Johannesburg, South Africa
Dagmar Whitaker, Cape Town, South Africa

12:30–13:30 Lunch Break

13:30 End of conference

G**Claus Garbe, MD**

Professor of Dermatology
Department of Dermatology
Eberhard Karls University
Liebermeister Str. 25
72076 Tuebingen
Germany
Phone: +49 7071 2987110
Email: claus.garbe@med.uni-tuebingen.de

Helen Gogas, MD

Professor of Medical Oncology
First Department of Medicine
Laiko Hospital
University of Athens
Agiou Thoma 17
Athens PK 11527
Greece
Phone: +30 21 0745 6353
Email: hgogas@hol.gr

Adele Green, MD

Royal Brisbane Hospital QLD 4029
300 Herston Rd
Herston QLD 4006, Brisbane
Australia
Phone: +61 7 33620234
Email: Adele.Green@qimrberghofer.edu.au

Jean Jacques Grob, MD

Professor of Dermatology
Service de Dermatology and Cancer
Research
Hospital de la Timone
264 Rue St. Pierre
13005 Marseille
France
Phone: +33 491 388591
Email: jean-jacques.grob@ap-hm.fr

H**Axel Hauschild, MD**

Professor of Dermatology
Department of Dermatology
University of Kiel
Rosalind-Franklin-Str. 7
24105 Kiel
Germany
Phone: +49 431 50021131
Email: ahauschild@dermatology.uni-kiel.de

Lucie Heinzerling, MD

Professor
Department of Dermatology
University Hospital of Erlangen
Ulmenweg 18
91054 Erlangen
Germany
Phone: +49 9131 8539037
Email: lucie.heinzerling@uk-erlangen.de

K**Suretha Kannenberg, MD**

NETCARE Kuils River Hospital
33 Van Riebeeck Rd, Kuils River
Cape Town, 7580
South Africa
Phone: +27 21 9006425/18
Email: info.krrc@mwebbiz.co.za

Roland Kaufmann, MD

Professor of Dermatology, Director
Department of Dermatology
Clinical Center J. W. Goethe University
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Germany
Phone: +49 69 63015311
Email: kaufmann@em.uni-frankfurt.de

Rainer Kunstfeld, MD

Professor of Dermatology
Währinger Str. 115
1180 Vienna
Austria
Phone: +43 1 4780033
Email: rainer.kunstfeld@meduniwien.ac.at

L

Alex Gil Landau, MD

Room 201 Fairfield Medical Suites
Wildernes Road
Claremont, Cape Town 7708
South Africa
Phone: +27 21 6740853
Email: info@plasticandcosmeticsurgery.co.za

Gary Levy, MD

Suite 1A Rochester Place
173 Rivonia Road
Johannesburg
South Africa
Phone: +27 11 8838497
Email: levy@pixie.co.za

M

Christopher Philipp Maske, MD

Lancet Corner Building
Cnr Stanley Avenue & Napier Road
Richmond, 2092
Johannesburg
South Africa
Phone: +27 11 3580800
Email: cmaske@gmail.com

Devan Moodley, MD

University of KwaZulu-Natal
King George V Ave
Durban, 4041
South Africa
Phone: +27 11 356 6900
Email: dvnierkerk@witsoncology.co.za

R

Bernardo Leon Rapoport, MD

Specialist Physician & Medical Oncologist
The Medical Oncology Centre
P.O. Box 2040
Parklands 2121
South Africa
Phone: +27 11 8804169/4222
Email: brapoport@rapoport.co.za

S

Dirk Schadendorf, MD

Professor of Dermatology
Department of Dermatology
University Hospital Essen
Hufelanstr. 55
45147 Essen
Germany
Phone: +49 201 7232430
Email: dirk.schadendorf@uk-essen.de

Peter Scott, MD

Suite C1, Block B, Rochester Place
Medical Centre
173 Rivonia Rd, Sandton
2057, Johannesburg
South Africa
Phone: +27 11 8832135
Email: peterscott@cinet.co.za

T

Charles Thatcher, MD

Eighth Avenue, Parktown North
Johannesburg, Gauteng
South Africa
Phone: +27 11 8860112
Email: charlest@histologic.co.za

V

Willie Visser, MD

Head of Dermatology
Division of Dermatology
Departement Geneeskunde Faculty
of Medicine and Health Sciences
Stellenbosch University
Posbus 241, Cape Town
South Africa
Phone: +27 21 9389322
Email: wvisser@sun.ac.za

Daniel A. Vorobiof, MD

Director
Sandton Oncology Centre
159 Rivonia Rd
Sandton, Johannesburg
South Africa
Phone: +27 11 8830900
Email: voro@global.co.za

W

Carla Wanblad, MD

Room G7
Midstream Hill Medical Park
Midstream Boulevard
Centurion
South Africa

Dagmar Whitaker, MD

1 Wytham Ave, Kenilworth Cape Town
Western Cape
South Africa
Phone: +27 21 7624779
Email: dwhitaker@mweb.co.za

12:45–13:45 **BMS** (gold sponsor)
Satellite Symposium with lunch bags
**Treatment of Metastatic Melanoma with Ipilimumab:
the South African Experience.**
Chair: Dagmar Whitaker

12:45–13:05 Immuno-Oncology Mode of Action
Carla Wanblad, Centurion, South Africa

13:05–13:25 Local Treatment Experience and
Retrospective Study
Daniel Vorobiof, Johannesburg, South Africa

13:25–13:45 Immuno-Related Adverse
Event Management
Bernardo Leon Rapoport, Parklands,
South Africa

Accommodation

MedConcept has obtained special accommodation rates for conference participants. Further information is available online at www.melanomaworldsociety.org/events

Climate

Cape Town is known for its Mediterranean climate with dry warm summers and mild winters. March is a perfect month for a visit in Cape Town. The average temperatures are between 14°C (57°F) and 25°C (77°F).

CME Credits

The First MWS International Educational Symposium – Skin Cancer Update 2017 is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The First MWS International Educational Symposium – Skin Cancer Update 2017 is designated for a maximum of **9 hours of European external CME credits**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

How to receive your CME Credits

To obtain CME credits please fill in the Evaluation Forms, which you will find in your course bag. To get your Certificate of Attendance with the CME credits please return the evaluation forms duly filled in to the registration desk.

Exhibition Opening Hours

Friday, March 3rd: 07:30–18:45

Saturday, March 4th: 07:30–13:30

Insurance

The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect to health and travel insurance.

Language

The official language of the meeting is English. Simultaneous translation will not be provided.

Letter of Invitation

To receive a personal letter of invitation for visa purposes, please contact: info@medconcept.org. The invitation is not a commitment on the part of the organizers to provide any financial support.

Meeting Organization

MEDCONCEPT 

MedConcept

Gesellschaft für medizinische Projekte mbH

Ms. Mirja Christ

Friedenstraße 58

15366 Neuenhagen b. Berlin, Germany

Phone: +49 (0)3342 42689-30

Fax: +49 (0)3342 42689-40

Email: mirja.christ@medconcept.org or info@medconcept.org

www.medconcept.org

Meeting Venue

The Rotunda

69 Victoria St

Camps Bay, Cape Town, 8001

South Africa

Phone: +27 (0)21 430 4444

Email: res@thebay.co.za

http://www.thebay.co.za/meeting_rotunda.html

The registration desk is situated at the entrance of the Rotunda.

Registration Desk Opening Hours

Thursday, March 2nd: 17:00–19:00 (early check-in)

Friday, March 3rd: 07:00–19:00

Saturday, March 4th: 07:00–14:00

Registration Fees

	Early registration until Nov. 30 th	From Dec. 1 st until Feb. 15 th	On site
Full Delegates	Africa		
	1,500 Rand	1,900 Rand	2,300 Rand
	Rest of World		
	300 Euro	350 Euro	400 Euro

After February 15th, 2017 all registrations have to be made onsite at the meeting venue.

Cancellation Policy

Cancellations must be received in writing by January 16th, 2017. No refunds will be granted after that date. To cancel a registration, please send an Email to info@medconcept.org. A processing fee of 150 Rand for Africa and 30 Euro for the Rest of the World will be deducted from each cancelled registration.

Substitutions are possible and must be received in writing by February 15th, 2017. To substitute a registration please send an email including the name of the original registrant and the name of the person substituting to info@medconcept.org.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

Visa Requirements

Participants are requested to check with the South African embassy in their home country or with their travel agency for visa requirements.

Zelboraf[®] in patients with BRAF^{V600E} mutation - positive metastatic melanoma: ^{1,2}

- Produces a robust increase in progression-free survival compared to dacarbazine: 6,9 months vs 1,6 months (HR 0,39; p < 0,0001) ¹
- Zelboraf[®] is associated with a highly significant improvement in response rate vs dacarbazine (59 % vs 11 %) ¹
- Medium time to response with Zelboraf[®] is 1,4 months ¹
- A well-characterised, manageable safety profile ²

Efficacy. Evidence. Experience.

Zelboraf[®]
vemurafenib

References: 1. McArthur GA, Chapman PB et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomized, open-label study. *Lancet Oncol* 2014;15:323-32. 2. Larkin J, del Vecchio M et al. Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicenter, safety study. *Lancet Oncol* 2014;15:436-44.

S4 ZELBORAF[®] 47/32.16/0147. Vemurafenib 240 mg per film-coated tablet. ZELBORAF[®] is indicated as monotherapy for the treatment of adult patients with BRAF V600E mutation-positive unresectable or metastatic melanoma. For full prescribing information refer to the package insert approved by the Medicines Regulatory Authority, Roche Products (Pty) Ltd, PO Box 55922, Northlands, 2116. Tel: 011 502 5000 or Toll-free on REAL (Roche Ethical Assistance Line): 0800 21 21 25. www.roche.co.za. SA/ZELB/1609/0005

**Early Bird Registration
until April 7, 2017**

Save the Date

June 29th–30th, 2017

Munich, Germany

www.melanomaglobal2017.org

7th European Post-Chicago Melanoma/Skin Cancer Meeting

REGISTRATION



Congress Presidents

Axel Hauschild, Kiel, Germany
Claus Garbe, Tuebingen, Germany

Under the auspices of the
European Association
of Dermato-Oncology



Gold



Silver



Bronze



Additional Sponsors

- Beiersdorf
- Fotofinder
- Galderma
- Genop Healthcare
- Provectus Biopharmaceuticals



YERVOY® (ipilimumab) For intravenous infusion

ADVANCING SCIENCE
IN METASTATIC MELANOMA

The science of immunotherapy

The significance of long-term survival*

For additional information please see Yervoy 5 mg/ml South African Package Insert. Bristol-Myers Squibb, Woodmead North Office Park, 54 Maxwell Drive, Woodmead, 2191. Tel: +27 11 808-5000
731ZA17PR00699-01

* *Hed FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723*

[S] **YERVOY®** 5 mg/ml solution for infusion. **Composition:** Each vial contains 5 mg/ml ipilimumab. **Inactive ingredients:** Tri-s-hydrochloride, sodium chloride, mannitol, penicilloic acid, polysorbate 80, sodium hydroxide (pH-adjustment), hydrochloric acid (pH-adjustment) and water for injection. **Indications:** YERVOY is indicated for the treatment of previously treated unresectable or metastatic melanoma. **Contraindications:** Hypersensitivity to ipilimumab or to any other ingredients in the formulation (see **Composition**). **Warnings and Special Precautions:** YERVOY is associated with inflammatory adverse reactions resulting from increased or excessive immune activity (immune-related adverse reactions), likely to be related to its mechanism of action. Immune-related adverse reactions, which can be severe or life-threatening, may involve the gastrointestinal, liver, skin, nervous, endocrine or other organ systems. While most immune-related adverse reactions occurred during the induction period, onset months after the last dose of YERVOY has also been reported. Unless an alternate aetiology has been identified, diarrhoea, increased stool frequency, bloody stool, liver function test (LFT) elevations, rash and endocrinopathy must be considered inflammatory and YERVOY-related. Early diagnosis and appropriate management are essential to minimise life-threatening complications. Systemic high-dose corticosteroid with or without additional immunosuppressive therapy may be required for management of severe immune-related adverse reactions. **Interactions:** YERVOY (ipilimumab) is a human monoclonal antibody that is not metabolised by cytochrome P450 enzymes (CYPs) or other metabolising enzymes, and is not expected to have an effect on CYPs or other metabolising enzymes in terms of inhibition or induction. **Pregnancy and Lactation:** Safety and efficacy in pregnancy and lactation have not been established. **Dosage and Directions for use:** YERVOY should be administered under the supervision of healthcare professionals experienced in the treatment of cancer. **Side effects:** YERVOY is most commonly associated with adverse reactions resulting from increased or excessive immune activity. Very commonly reported adverse reactions (occurring at $\geq 10\%$) were diarrhoea, rash, pruritus, fatigue, nausea, vomiting, decreased appetite, and abdominal pain. The majority of adverse reactions were mild to moderate (Grade 1 or 2). **Registration number:** 47/30.1/0522. **Pharmaceutical classification:** A.30.1 Antibodies. **Name and business address of the holder of the certificate of registration:** Bristol-Myers Squibb (Pty) Ltd., Woodmead North Office Park, 54 Maxwell Drive, Woodmead, 2191. Tel. 011 808 5000. **Company Registration No.:** 1956/00115/07. For full prescribing information refer to the South African package insert. **Dated:** 30 September 2016.



Bristol-Myers Squibb
Together we can prevail.®

